K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

The abstract of the presentation is available at https://www.abstractsonline.com/pp8/#!/20273/presentation/3006. The abstract of the presentation is available at https://www.abstractsonline.com/pp8/#!/20273/presentation/3006. More information about the AACR Annual Meeting 2025 can be found on the event website at the following link:AACR Annual Meeting 2025 | Meetings | AACR About K-679 K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using...

The abstract of the presentation is available at
https://www.abstractsonline.com/pp8/#!/20273/presentation/3006.

More information about the AACR Annual Meeting 2025 can be found on the event website at the following link: AACR Annual Meeting 2025 | Meetings | AACR

About K-679
K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently at non-clinical stage. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 40 DM1 molecules per antibody, significantly higher than conventional ADCs.

In non-clinical studies, K-679 has demonstrated potent anti-tumor effects in xenograft models, outperforming conventional ADCs. Notably, K-679 has shown remarkable efficacy in EGFR‑positive and -negative heterogeneous tumors, exhibiting significant bystander killing effects.

Media Contact:
Ian Mehr
Kowa Research Institute, Inc.
919-433-1600
[email protected]

Logo - https://mma.prnewswire.com/media/320297/kowa_research_institute_inc_logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/k-679-a-novel-antibody-drug-loaded-unimicelle-conjugate-with-ultra-high-drug-loading-capacity-demonstrates-superior-efficacy-in-egfr-expressing-solid-tumors-302430671.html